JAZZ · Jazz Pharmaceuticals plc · Documents

Feb 28

Current report 8-K

Financial results

Feb 28

Annual report 10-K FY2023, ended Dec 31

Annual report for FY2023

Revenue $3.83B ▲ 4.8% Net income $414.83M Diluted EPS $6.10

Feb 27

Current report 8-K Events of Feb 23

Director or officer change, or executive pay

Feb 21

Current report 8-K

Director or officer change, or executive pay, Regulation FD disclosure

Jan 25

Current report 8-K Events of Jan 19

Entered into a material agreement, New debt or off-balance-sheet obligation

Jan 8

Earnings call

Q4 2023 earnings call

Jan 8

Current report 8-K

Financial results

Dec 15

Current report 8-K Events of Dec 11

Director or officer change, or executive pay

Nov 8

Earnings call

Q3 2023 earnings call

Nov 8

Current report 8-K

Financial results

Nov 8

Quarterly report 10-Q FY2023 Q3, ended Sep 30

Quarterly report for FY2023 Q3

Revenue $972.14M ▲ 3.3% Net income $146.82M Diluted EPS $2.14

Sep 12

Current report 8-K Events of Sep 6

Director or officer change, or executive pay

Aug 9

Earnings call

Q2 2023 earnings call

Aug 9

Current report 8-K

Financial results

Aug 9

Quarterly report 10-Q FY2023 Q2, ended Jun 30

Quarterly report for FY2023 Q2

Revenue $957.32M ▲ 2.6% Net income $104.44M ▲ 201.3% Diluted EPS $1.52 ▲ 176.4%

Jul 26

Proxy statement DEFA14A

Proxy statement

Jun 22

Current report 8-K

Regulation FD disclosure

Jun 16

Proxy statement DEF 14A

Proxy statement

Jun 16

Annual report to holders ARS

Annual report to holders

Jun 16

Proxy statement DEFA14A

Proxy statement

Jun 6

Proxy statement PRE 14A

Proxy statement

May 10

Earnings call

Q1 2023 earnings call

May 10

Current report 8-K

Financial results

May 10

Quarterly report 10-Q FY2023 Q1, ended Mar 31

Quarterly report for FY2023 Q1

Revenue $892.81M ▲ 9.7% Net income $69.42M ▲ 4114.9% Diluted EPS $1.04 ▲ 3366.7%

May 1

Annual report 10-K/A Ended Dec 31

Annual report for the period ended Dec 31, 2022

Mar 1

Earnings call

Q4 2022 earnings call

Mar 1

Current report 8-K

Financial results

Mar 1

Annual report 10-K FY2022, ended Dec 31

Annual report for FY2022

Revenue $3.66B ▲ 18.3% Net loss $224.06M Diluted EPS -$3.58

Jan 9

Current report 8-K

Financial results

Jan 4

Current report 8-K Events of Jan 3

Other events

Dec 21

Current report 8-K

Other events

Dec 5

Current report 8-K Events of Nov 29

Completed an acquisition or sale of assets

Nov 14

Current report 8-K

Other events

Nov 9

Earnings call

Q3 2022 earnings call

Nov 9

Current report 8-K

Financial results

Nov 9

Quarterly report 10-Q FY2022 Q3, ended Sep 30

Quarterly report for FY2022 Q3

Revenue $940.65M ▲ 12.2% Net loss $19.65M Diluted EPS -$0.31

Oct 19

Current report 8-K

Other events

Aug 3

Earnings call

Q2 2022 earnings call

Aug 3

Current report 8-K

Financial results

Aug 3

Quarterly report 10-Q FY2022 Q2, ended Jun 30

Quarterly report for FY2022 Q2

Revenue $932.88M ▲ 24.1% Net income $34.67M Diluted EPS $0.55

Jul 22

Proxy statement DEFA14A

Proxy statement

Jul 15

Proxy statement DEFA14A

Proxy statement

Jul 7

Proxy statement DEFA14A

Proxy statement

Jun 17

Proxy statement DEFA14A

Proxy statement

Jun 13

Proxy statement DEF 14A Meeting Jul 28, 2022

Proxy statement

Jun 13

Proxy statement DEFA14A

Proxy statement

May 31

Proxy statement PRE 14A Meeting Jul 28, 2022

Proxy statement

May 4

Current report 8-K

Financial results

May 4

Earnings call

Q1 2022 earnings call

May 4

Current report 8-K

Other events